Intra-Cellular Therapies to Participate at Upcoming Investor Conferences

NEW YORK, Nov. 23, 2015 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it will participate at the following investor conferences in December 2015:

  • 27th Annual Piper Jaffray Healthcare Conference taking place in New York City from December 1-2, 2015. Sharon Mates, Ph.D., Chief Executive Officer and Chairman, will participate in a Fireside Chat, on December 1, 2015 at 2:30 p.m. Eastern Time.
  • Leerink Partners' POLARxPRESS Bus Tour taking place on December 2, 2015 in New York City. Sharon Mates, Ph.D., will present at 2:35 p.m. Eastern Time.

The live webcast at Piper Jaffray Healthcare Conference can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

CONTACT: Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) 212-213-0006

Source:Intra-Cellular Therapies, Inc.